Millipore Sigma Vibrant Logo

676496 VEGF Inhibitor, CBO-P11 - Calbiochem

VEGF Inhibitor, CBO-P11, is a macrocyclic peptide derived from residues 79-93 of VEGF. Mediates VEGF binding to VEGFR-2. Blocks VEGF165 binding to VEGFR1 and 2 (IC50 = 700 nM & 1.3 µM, respectively).

VEGF Inhibitor, CBO-P11 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: Cyclo-VEGI, cyclic(D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI

Primary Target: Blocks the binding of VEGF165 to its receptors
View This Product on Sigma-Aldrich
676496
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

Empirical Formula
C₉₀H₁₄₀N₂₈O₂₂S

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
676496-1MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 1 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA macrocyclic 17-amino acid peptide derived from residues 79 - 93 of vascular endothelial growth factor that mediate its binding to VEGFR-2. It blocks the binding of VEGF165 to its receptors (IC50 = 700 nM for VEGFR1, 1.3 µM for VEGFR2) and exhibits anti-angiogenic activity as well as other VEGFR-mediated cellular functions, such as proliferation (IC50 = 5.8 µM), migration (IC50 = 8.2 µM), and activation of MAP kinases. Its anti-angiogenic activity has been successfully demonstrated in vivo using chick embryos and nude mice tumor models of human intracranial and syngeneic glioma.
      Catalogue Number676496
      Brand Family Calbiochem®
      SynonymsCyclo-VEGI, cyclic(D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI
      References
      ReferencesZilberberg, L., et al. 2003. J. Biol. Chem. 278, 35564.
      Product Information
      ATP CompetitiveN
      FormWhite lyophilized solid
      FormulationSupplied as a trifluoroacetate salt.
      Hill FormulaC₉₀H₁₄₀N₂₈O₂₂S
      Chemical formulaC₉₀H₁₄₀N₂₈O₂₂S
      Hygroscopic Hygroscopic
      ReversibleN
      Quality LevelMQ100
      Applications
      ApplicationVEGF Inhibitor, CBO-P11, is a macrocyclic peptide derived from residues 79-93 of VEGF. Mediates VEGF binding to VEGFR-2. Blocks VEGF165 binding to VEGFR1 and 2 (IC50 = 700 nM & 1.3 µM, respectively).
      Biological Information
      Primary TargetBlocks the binding of VEGF165 to its receptors
      Primary Target IC<sub>50</sub>700 nM for VEGFR1, 1.3 µM for VEGFR2
      Purity≥97% by HPLC
      Physicochemical Information
      Cell permeableN
      Peptide Sequencecyclic(D-Phe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu)
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Carcinogenic / Teratogenic
      Storage -20°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      676496-1MGCN 04055977260489

      Documentation

      VEGF Inhibitor, CBO-P11 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      VEGF Inhibitor, CBO-P11 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      676496

      参考資料

      参考資料の概要
      Zilberberg, L., et al. 2003. J. Biol. Chem. 278, 35564.

      引用

      Title
    • Vivian Y. Shin, et al. (2005) Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Molecular Cancer Research 3, 607-615.
      		•
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision16-September-2008 RFH
      SynonymsCyclo-VEGI, cyclic(D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI
      DescriptionA macrocyclic, 17-amino acid peptide derived from residues 79-93 of vascular endothelial growth factor (VEGF) that mediates the binding of VEGF to its receptor, VEGFR-2. Blocks the binding of VEGF165 to its receptors (IC50 = 70 nM for VEGFR-1, 1.3 µM for VEGFR-2) and exhibits anti-angiogenic properties. Also reported to block other VEGF-mediated cellular functions such as proliferation (IC50 = 5.8 µM), migration (IC50 = 8.2 µM), and activation of MAP kinases. Also reported to exhibit anti-angiogenic properties in vivo using chick embryo and nude mouse tumor models of human intracranial and syngeneic glioma.
      FormWhite lyophilized solid
      FormulationSupplied as a trifluoroacetate salt.
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₉₀H₁₄₀N₂₈O₂₂S
      Peptide Sequencecyclic(D-Phe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu)
      Purity≥97% by HPLC
      SolubilityDMSO (5 mg/ml) or H₂O
      Storage Protect from light
      -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Carcinogenic / Teratogenic
      ReferencesZilberberg, L., et al. 2003. J. Biol. Chem. 278, 35564.
      Citation
    • Vivian Y. Shin, et al. (2005) Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Molecular Cancer Research 3, 607-615.
      		•